Evolutionary Tree Capital Management LLC Decreases Stock Position in Ascendis Pharma A/S (NASDAQ:ASND)

Evolutionary Tree Capital Management LLC reduced its stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 8.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 30,115 shares of the biotechnology company's stock after selling 2,638 shares during the quarter. Ascendis Pharma A/S comprises 4.2% of Evolutionary Tree Capital Management LLC's holdings, making the stock its 8th largest position. Evolutionary Tree Capital Management LLC's holdings in Ascendis Pharma A/S were worth $4,146,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently bought and sold shares of the stock. FIL Ltd grew its position in shares of Ascendis Pharma A/S by 13.9% during the 4th quarter. FIL Ltd now owns 729,275 shares of the biotechnology company's stock worth $100,399,000 after purchasing an additional 89,016 shares in the last quarter. American Century Companies Inc. increased its stake in Ascendis Pharma A/S by 17.5% during the 4th quarter. American Century Companies Inc. now owns 407,294 shares of the biotechnology company's stock worth $56,072,000 after acquiring an additional 60,548 shares during the period. Artisan Partners Limited Partnership raised its holdings in Ascendis Pharma A/S by 0.9% in the 4th quarter. Artisan Partners Limited Partnership now owns 4,450,420 shares of the biotechnology company's stock valued at $612,689,000 after acquiring an additional 39,309 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Ascendis Pharma A/S by 94.4% during the 4th quarter. JPMorgan Chase & Co. now owns 77,427 shares of the biotechnology company's stock valued at $10,659,000 after acquiring an additional 37,593 shares during the period. Finally, abrdn plc raised its stake in Ascendis Pharma A/S by 18.3% in the fourth quarter. abrdn plc now owns 187,180 shares of the biotechnology company's stock valued at $25,769,000 after purchasing an additional 28,967 shares in the last quarter.

Remove Ads

Analyst Ratings Changes

ASND has been the subject of a number of research analyst reports. Morgan Stanley set a $180.00 price target on Ascendis Pharma A/S in a report on Tuesday, February 18th. JPMorgan Chase & Co. upped their price objective on shares of Ascendis Pharma A/S from $168.00 to $200.00 and gave the stock an "overweight" rating in a research report on Tuesday, March 18th. Evercore ISI boosted their target price on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the stock an "outperform" rating in a research note on Tuesday, February 18th. UBS Group assumed coverage on Ascendis Pharma A/S in a report on Tuesday, January 7th. They set a "buy" rating and a $196.00 price objective on the stock. Finally, The Goldman Sachs Group upped their target price on Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a "buy" rating in a report on Thursday, February 13th. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $204.64.

Ascendis Pharma A/S Stock Down 1.0 %

NASDAQ ASND traded down $1.58 during trading hours on Tuesday, reaching $153.92. 255,010 shares of the company were exchanged, compared to its average volume of 478,466. The stock has a market capitalization of $9.38 billion, a P/E ratio of -21.68 and a beta of 0.54. Ascendis Pharma A/S has a 1 year low of $111.09 and a 1 year high of $169.37. The business's 50 day simple moving average is $149.43 and its 200-day simple moving average is $137.82.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, topping analysts' consensus estimates of ($1.32) by $0.64. As a group, sell-side analysts anticipate that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.